Transgender individuals are gradually increasing in worldwide. Hormonal therapies may impact cardiovascular mortality, kidney function and transplant stability, the inverse is also true: immunosuppressive agents, particularly high-dose glucocorticoids used to treat acute rejection episodes, may adversely affect mental health, potentially complicating gender-affirming treatment. We aim to provide a comprehensive summary of the status of kidney transplantation in transgender individuals. A comprehensive search was conducted using MeSH keywords, including: “transgender,” “kidney function,” “hormone therapy,” “renal transplantation.” One investigator screened articles for eligibility within the PubMed, MEDLINE, Google Scholar databases. A total of 36 full-text articles were systematically analyzed based on predefined inclusion criteria. The analysis revealed available data, though limited to case-level evidence, support the safety and efficacy of kidney transplantation in transgender individuals receiving gender-affirming hormone therapy (GAHT). Continued hormone therapy is not only medically feasible but essential for the well-being and identity affirmation of transgender patients. Treatment plans must be personalized, taking into account comorbid psychiatric conditions, medication side effect profiles, and the patient’s goals related to physical appearance and gender identity. Preoperative evaluation should include thorough endocrinologic and psychiatric assessment, and postoperative care should be guided by ongoing collaboration between transplant teams, endocrinologists, and mental health specialists. The presence of GAHT should not preclude transplantation but rather prompt careful, individualized assessment and interdisciplinary management. Establishing standardized protocols and inclusive clinical pathways will be key to ensuring that transgender patients receive equitable and affirming access to life-saving kidney transplantation.
D’hooreLT’SjoenG.Gender-affirming hormone therapy: an updated literature review with an eye on the future. J Intern Med2022; 291(5): 574–592.
2.
GoodmanMAdamsNCorneilT, et al. Size and distribution of transgender and gender nonconforming populations: a narrative review. Endocrinol Metab Clin North Am2019; 48(2): 303–321.
3.
MeyerGMayerMMondorfA, et al. Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria. Eur J Endocrinol2020; 182(2): 149–156.
4.
CunhaFSDomeniceSSirciliMHP, et al. Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women. Clinics2018; 73(3): 7.
5.
MuellerAKiesewetterFBinderH, et al. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab2007; 92(9): 3470–3475.
6.
NeugartenJGolestanehL.Gender and the prevalence and progression of renal disease. Adv Chronic Kidney Dis2013; 20(5): 390–395.
7.
JafarTHSchmidCHStarkPC, et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant2003; 18(10): 2047–2053.
8.
NautiyalABagchiSBansalSB.Gender and kidney transplantation. Front Nephrol2024; 4(4): 1360856.
9.
Katz-GreenbergGShahS.Sex and gender differences in kidney transplantation. Semin Nephrol2022; 42: 219–229.
10.
AhearnPJohansenKLTanJC, et al. Sex disparity in deceased-donor kidney transplant access by cause of kidney disease. Clin J Am Soc Nephrol2021; 16: 241–250.
11.
VinsonAJ.Gender disparities in access to kidney transplant: inequities in the inequity. Kidney Int Rep2022; 7: 1145–1148.
12.
DudleyCRKJohnsonRJThomasHL, et al. Factors that influence access to the national renal transplant waiting list. Transplantation2009; 88: 96–102.
13.
GillJSHendrenEDongJ, et al. Differential association of body mass index with access to kidney transplantation in men and women. Clin J Am Soc Nephrol2014; 9: 951–959.
14.
HumbleRMImborekKLNislyN, et al. Common hormone therapies used to care for transgender patients influence laboratory results. J Appl Lab Med2019; 3: 799–814.
15.
SoRelleJAJiaoRGaoE, et al. Impact of hormone therapy on laboratory values in transgender patients. Clin Chem2019; 65: 170–179.
16.
KrupkaECurtisSFergusonT, et al. The effect of gender-affirming hormone therapy on measures of kidney function: a systematic review and meta-analysis. Clin J Am Soc Nephrol2022; 17(9): 1305–1315.
17.
VitaRSettineriSLiottaM, et al. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: a cohort study. Maturitas2018; 107: 92–96.
18.
RobertsTKKraftCSFrenchD, et al. Interpreting laboratory results in transgender patients on hormone therapy. Am J Med2014; 127: 159–162.
19.
GiltayEJVerhoefPGoorenLJ, et al. Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. Atherosclerosis2003; 168: 139–146.
20.
Turino MirandaKGreeneDNCollisterD, et al. A holistic framework for the evaluation of kidney function in a gender-diverse landscape. Am J Kidney Dis2024; 84(2): 232–240.
21.
KhuranaKKNavaneethanSDArrigainS, et al. Serum testosterone levels and mortality in men with CKD stages 3-4. Am J Kidney Dis2014; 64(3): 367–374.
22.
HolleyJLSchmidtRJ.Changes in fertility and hormone replacement therapy in kidney disease. Adv Chronic Kidney Dis2013; 20(3): 240–245.
23.
GrossmannMHoermannRNg Tang FuiM, et al. Sex steroids levels in chronic kidney disease and kidney transplant recipients: associations with disease severity and prediction of mortality. Clin Endocrinol2015; 82(5): 767–775.
24.
McCannEBrownM.Vulnerability and psychosocial risk factors regarding people who identify as transgender. A systematic review of the research evidence. Issues Ment Health Nurs2018; 39(1): 3–15.
25.
YuJRavelVAYouAS, et al. Association between testosterone and mortality risk among U.S. males receiving dialysis. Am J Nephrol2017; 46(3): 195–203.
26.
AraujoABEscheGRKupelianV, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab2007; 92(11): 4241–4247.
27.
YiSSelvinERohrmannS, et al. Endogenous sex steroid hormones and measures of chronic kidney disease (CKD) in a nationally representative sample of men. Clin Endocrinol2009; 71: 246–252.
28.
CarreroJJStenvinkelP.The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant2012; 27: 4030–4041.
29.
SzekacsBVajoZVarbiroS, et al. Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. BJOG2000; 107(8): 1017–1021.
30.
MonsterTBJanssenWMde JongPE, et al. Prevention of renal and vascular end stage disease study group. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med2001; 161(16): 2000–2005.
31.
DixonAMaricC.17beta-estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling. Am J Physiol Renal Physiol2007; 293(5): F1678–F1690.
32.
T’SjoenGArcelusJDe VriesALC, et al. European society for sexual medicine position statement. “Assessment and hormonal management in adolescent and adult trans people, with attention for sexual function and satisfaction”. J Sex Med2020; 17(4): 570–584.
33.
Aparicio-GarcíaMEDíaz-RamiroEMRubio-ValdehitaS, et al. Health and well-being of cisgender, transgender and non-binary young people. Int J Environ Res Public Health2018; 15(10): 2133.
34.
TackLJWCraenMLapauwB, et al. Proandrogenic and antiandrogenic progestins in transgender youth: differential effects on body composition and bone metabolism. J Clin Endocrinol Metab2018; 103(6): 2147–2156.
35.
KlaverMde MutsertRWiepjesCM, et al. Early hormonal treatment affects body composition and body shape in young transgender adolescents. J Sex Med2018; 15(2): 251–260.
36.
VlotMCWiepjesCMde JonghRT, et al. Gender-affirming hormone treatment decreases bone turnover in transwomen and older transmen. J Bone Miner Res2019; 34(10): 1862–1872.
37.
WiepjesCMVlotMCde BlokCJM, et al. Bone geometry and trabecular bone score in transgender people before and after short- and long-term hormonal treatment. Bone2019; 127: 280–286.
38.
Van CaenegemEWierckxKTaesY, et al. Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study. Osteoporos Int2015; 26(1): 35–47.
39.
ChrisostomoKRSkareTLChrisostomoHR, et al. Transwomen and bone mineral density: a cross-sectional study in Brazilian population. Br J Radiol2020; 93(1111): 20190935.
40.
KlinkDCarisMHeijboerA, et al. Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. J Clin Endocrinol Metab2015; 100(2): E270–E275.
41.
SoferYYaishIYaronM, et al. Differential endocrine and metabolic effects of testosterone suppressive agents in transgender women. Endocr Pract2020; 26(8): 883–890.
42.
MadsenCMvan DijkDWiepjesCM, et al. Erythrocytosis in a large cohort of trans men using testosterone: a long-term follow-up. J Clin Endocrinol Metab2020; 105(12): 4131–4139.
43.
KuceraHSchwarzenbacherFSchäfferL, et al. Care in nephrology: an emerging challenge. J Nephrol2023; 36(3): 453–463.
44.
GavaGManciniICerpoliniS, et al. Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration. Clin Endocrinol2018; 89(6): 878–886.
45.
JueJSAlameddineMCiancioG.Kidney transplantation in transgender patients. Curr Urol Rep2020; 21(1): 1.
46.
RamadanOINajiALevineMH, et al. Kidney transplantation and donation in the transgender population: a single-institution case series. Am J Transplant2020; 20(10): 2899–2904.
47.
WierckxKMuellerSWeyersS, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med2012; 9(10): 2641–2651.
48.
LeeKChuziSKatzJ, et al. Heart-kidney transplantation in a transgender woman. JACC Case Rep2022; 4(23): 101523.
49.
SaferJDTangprichaV.Care of transgender persons. N Engl J Med2019; 381: 2451–2460.
